• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

neovasc

EuroPCR 2019: Elixir Medical touts DynamX

May 23, 2019 By Brad Perriello

Elixir Medical touted clinical and imaging results from a study of its DynamX drug-eluting stent, which is designed to restore normal pulsatility and adaptive remodeling in blood vessels after treating a coronary lesion. DynamX, introduced in 2017 at the annual Transcatheter Cardiovascular Therapeutics meeting, is a cobalt-chromium stent with a biodegradable polymer coating that releases novolimus. […]

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Featured Tagged With: Biotronik, Corindus Vascular Robotics, Elixir Medical Corp., EuroPCR 2019, neovasc, Pi-Cardia

Neovasc surges on two-year Reducer results

May 23, 2019 By Brad Perriello

Two-year data from a trial of the Reducer anti-angina device made by Neovasc (NSDQ:NVCN), published this week in the International Journal of Cardiology, bore out earlier safety and efficacy results but showed no effect on the progression of coronary artery disease. The study examined angina symptoms, quality of life and adverse events at two years, […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Wall Street Beat Tagged With: neovasc

Neovasc closes $12m offering

May 17, 2019 By Fink Densford

Neovasc (NSDQ:NVCN) said yesterday that it closed the $11.5 million offering it announced earlier this week. Proceeds from the offering will be used to support continued development and commercialization of its Reducer device, and development of its Tiara device, the Vancouver-based company said. In the offering, Neovasc said that it sold a 15% original issue discount convertible […]

Filed Under: Business/Financial News, Wall Street Beat Tagged With: neovasc

Neovasc raises $12m

May 14, 2019 By Fink Densford

Neovasc (NSDQ:NVCN) said today that it raised approximately $11.5 million through the combined sale of shares of its stock and convertible debt. The Vancouver-based company said that it inked an agreement to sell Strul Medical Group a 15% original issue discount convertible note with a face value of $11.5 million, expecting to see gross proceeds of […]

Filed Under: Business/Financial News, Wall Street Beat Tagged With: neovasc

Neovasc plunges on Q1 misses

May 10, 2019 By Brad Perriello

Neovasc (NSDQ:NVCN) shares are taking a beating this morning after the company released first-quarter results yesterday that badly missed the consensus forecast. Vancouver-based Neovasc pared its losses by -85.7% to -$7.9 million, or -21¢ per share, on sales growth of 72.3% to $585,800 compared with Q1 2018. Analysts on Wall Street were looking for losses […]

Filed Under: Cardiovascular, Mergers & Acquisitions, Replacement Heart Valves, Wall Street Beat Tagged With: neovasc

Neovasc settles final spat with Edwards unit CardiAQ Valve

April 18, 2019 By Fink Densford

Neovasc (NSDQ:NVCN) said late yesterday that it resolved the last remaining patent litigation between it and Edwards Lifesciences (NYSE:EW) subsidiary CardiAQ Valve Technologies by adding members of CardiAQ as co-inventors of the patents in dispute. Vancouver-based Neovasc said that it added CardiAQ’s Jeremy Brent Ratz and Arshad Quadri as co-inventors of three patents, each of which was related […]

Filed Under: Featured, Legal News, Replacement Heart Valves, Wall Street Beat Tagged With: CardiAQ Valve Technologies, Edwards Lifesciences, neovasc

Neovasc gains on Reducer study

April 17, 2019 By Brad Perriello

Shares of Neovasc (NSDQ:NVCN) are up today after the medical device company released study results showing that its Reducer device for treating angina doesn’t worsen heart function and may in fact help. The Vancouver-based company said the 24-patient study of patients treated with Reducer, which is designed to narrow the coronary sinus, showed no significant […]

Filed Under: Cardiac Implants, Clinical Trials, Featured, Wall Street Beat Tagged With: neovasc

Neovasc shares tumble on 2018 earnings release

March 22, 2019 By Fink Densford

Shares in Neovasc (NSDQ:NVCN) have fallen nearly 10% today after the medical device maker posted full year 2018 earnings that showed losses growing to more than triple what it reported in 2017. The Vancouver-based company posted losses of $109.1 million, or $7.63 per share, on sales of $1.7 million, seeing losses grow 338.7% while sales shrunk […]

Filed Under: Business/Financial News, MassDevice Earnings Roundup, Wall Street Beat Tagged With: neovasc

Neovasc claims win in German TMVR patent case against Edwards unit CardiAQ Valve

March 21, 2019 By Brad Perriello

Neovasc (NSDQ:NVCN) today claimed a win in its patent infringement war with Edwards Lifesciences (NYSE:EW) subsidiary CardiAQ Valve Technologies, saying a German appeals court dismissed a case there. In June 2017 the District Court in Munich ruled that CardiAQ Valve contributed to the creation of Neovasc’s Tiara transcatheter mitral valve replacement, awarding”co-entitlement” rights to the patent in […]

Filed Under: Featured, Legal News, Replacement Heart Valves, Wall Street Beat Tagged With: CardiAQ Valve Technologies, Edwards Lifesciences, neovasc

Neovasc retains EC Marking after EU surveillance audit

March 15, 2019 By Fink Densford

Updated to correct from CE Marking to EC Marking. Neovasc (NSDQ:NVCN) said yesterday that it successfully completed its 2019 mandatory surveillance audit with its notified body in the European Union. The Vancouver-based company said that as a result of the successful audit, and its maintenance of the ISO 13485: 2016 certification of its quality management system, […]

Filed Under: Business/Financial News, Regulatory/Compliance Tagged With: neovasc

Neovasc prices $5m offering

March 13, 2019 By Fink Densford

Neovasc (NSDQ:NVCN) today priced an upcoming offering looking to raise $5 million to support its Tiara and Reducer devices. In the round, the Vancouver-based company will look to float approximately 11.1 million shares of its common stock at a price of 45¢ per share. The offering is expected to close on March 15, the company said. […]

Filed Under: Business/Financial News, Wall Street Beat Tagged With: neovasc

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Interim pages omitted …
  • Go to page 8
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS